Crossmark

Evaluating the impact of atezolizumab on febrile neutropenia occurrence in patients with NSCLC undergoing chemotherapy in Japan: a real-world post-marketing database study

Crossref DOI link: https://doi.org/10.1007/s10147-024-02669-y

Published Online: 2024-12-16

Published Print: 2025-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Nakane, Sayuri

Yuri, Akinori

Miyano, Yuki

Yamada, Kana

Nakatsuji, Erika

Takei, Nobuki

Igarashi, Yasuhiro

Harada, Ryousuke
Funding

Funding for this research was provided by:

Chugai Pharmaceutical
License Information

Text and Data Mining valid from 2024-12-16

Version of Record valid from 2024-12-16
More Information

Article History

Received: 24 May 2024

Accepted: 24 November 2024

First Online: 16 December 2024

Declarations

:

: All the authors are employees of Chugai Pharmaceutical Co., Ltd. and have no conflicts of interest to disclose.

Document is current

Any future updates will be listed below